Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

(expenses): Foreign exchange gain (loss) (1,032) 1,032 h - Investment and other income (498) 544 i 46 Interest expense on long-term debt (10,639) 559 j (10,080) Write-down and other deferred financing charges (3,000) 3,000 k - Write-down / loss on redemption of investments (10,964) 10,964 l - Write-down of assets held for sale (1,283) 1,283 m - Write-down of goodwill (50,285) 50,285 n - ------------------------------------------------------------------------- ------------------------------------------------------------------------- (77,701) 67,667 (10,034) ------------------------------------------------------------------------- ------------------------------------------------------------------------- (Loss) income from continuing operations before income taxes (79,540) 77,971 (1,569) Income tax (recovery) expense (2,577) 3,629 o 1,052 ------------------------------------------------------------------------- ------------------------------------------------------------------------- (Loss) income from continuing operations (76,963) 74,342 (2,621) Net loss from discontinued operations, net of income taxes - - - ------------------------------------------------------------------------- Net (loss) income for the period $ (76,963) $ 74,342 $ (2,621) ------------------------------------------------------------------------- Basic and diluted net loss per common share from continuing operations $ (0.90) $ (0.03)
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The 2015 ... in-depth study on the current state of the global Propanol market with a focus ... CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, ...
(Date:7/30/2015)... over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor ... 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... and designed for continuous operation up to 1500 bar. The sanitary design gauge ... and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... EMERYVILLE, Calif., Aug. 3 Bionovo, Inc. (Nasdaq: ... second quarter of fiscal year 2009 ended June 30, 2009 on Monday, ... cast to review the financial results on Monday, August 10, 2009 at ... the call by dialing (800) 860-2442 or (412) 858-4600, or can listen ...
... , , , ... Inc. (Nasdaq: SNMX ), a leading company focused on ... the food, beverage, and ingredient supply industries, and Firmenich SA, the ... have entered into a collaborative research, development, commercialization and license agreement ...
... , , EMERYVILLE, ... NBY ) today announced that Roy J. Wu ... business development. Wu brings to NovaBay more than 30 ... with increasingly responsible management positions in global business development, ...
Cached Biology Technology:Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009 2SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 2SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 3SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 4SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 5NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development 2NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... a common feature of prion disease-affected human, mouse, and ... Neena Singh and colleagues at Case Western Reserve University ... findings, published March 13 in the open-access journal ... of neurotoxicity in prion disorders, and novel avenues for ...
... Kansas State,University, with collaboration from Epitopix LLC, have ... E. coli O157 in beef cattle. ... the post-harvest food safety,aspect, whether it,s E. ... College of Veterinary Medicine. Thomson is the Jones,Professor ...
... German . The Aarhus University ... between the many conference participants and according to ... Kyoto was very successful in doing so: "I am ... will undoubtedly contribute significantly to the future climate debate ...
Cached Biology News:Iron is involved in prion disease-associated neuronal demise 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2Seven recommendations from Aarhus to COP15 2Seven recommendations from Aarhus to COP15 3
Recognizes the ~115 kDa NMDA receptor NR1 subunit in rat cortex tissue extracts....
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
... Monoclonal Anti-β-Tubulin IV Recognizes ... C-terminal sequence of β-tubulin isotype ... tubulin isotypes is observed. ascites ... the C-terminal sequence of β-tubulin ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Biology Products: